| Bioactivity | NR-11c is a selective and potent p38α PROTAC degrader. NR-11c effectively degrades p38α in a variety of tumor cells. When administered intraperitoneally or intravenously to mice, NR-11c primarily acts in the liver. NR-11c can be used in cancer research. (Pink: p38α inhibitor 5 (HY-159799); Black: linker (HY-159800); Blue: VHL E3 ligase ligand (HY-112078))[1]. | ||||||||||||
| Invitro | NR-11c (1-1000 nM；24 小时) 在多种肿瘤细胞系中能有效降解 p38α ，其中在 MDA-MB-231 细胞中，DC50 为 11.55 nM[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> NR-11c 相关抗体: Western Blot Analysis[1] Cell Line: | ||||||||||||
| In Vivo | NR-11c (15 mg/kg；瘤内/瘤周注射；单剂量) 在小鼠乳腺癌模型中，两种给药方式均可下调肿瘤中的 p38α 水平[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||
| Formula | C59H71BrF2N10O8S | ||||||||||||
| Molar Mass | 1198.22 | ||||||||||||
| Appearance | 固体 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Cubillos-Rojas M, et al. Synthesis and Biological Activity of a VHL-Based PROTAC Specific for p38α. Cancers (Basel). 2023 Jan 18;15(3):611. |